What has FDA cited under 21 CFR 211.180(a)?

1 DSRV article cite 21 CFR 211.180(a). Enforcement cases behind them: FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018. Inspection exposure across them: 1 high.

What does DSRV recommend for 21 CFR 211.180(a)?

From the newest article (FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say): The separating control is whether audit trail review, OOS-rate trending, and validated technical access controls run as scheduled operations, because FDA reads an undetected manipulation pattern as a failed quality system rather than an analyst problem. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 high

21 CFR 211.180(a)

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.180(a): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under 21 CFR 211.180(a)?: 1 DSRV article cite 21 CFR 211.180(a). Enforcement cases behind them: FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018. Inspection exposure across them: 1 high.
What does DSRV recommend for 21 CFR 211.180(a)?: From the newest article (FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say): The separating control is whether audit trail review, OOS-rate trending, and validated technical access controls run as scheduled operations, because FDA reads an undetected manipulation pattern as a failed quality system rather than an analyst problem. DSRV is decision support, not legal advice; verify against the official source each article names.

March 20267 min readHigh exposurecited as a tag
FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say
Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't.
Case
FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018.
DSRV take
The separating control is whether audit trail review, OOS-rate trending, and validated technical access controls run as scheduled operations, because FDA reads an undetected manipulation pattern as a failed quality system rather than an analyst problem.

Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.180(a). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.180(a)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.